Neurosteroids: A Potential Therapeutic Agent in Alzheimerâs Disease
*Corresponding Author:Received Date: Nov 16, 2023 / Published Date: May 12, 2025
Citation: Jain AS (2025) Neurosteroids–A Potential Therapeutic Agent in Alzheimer’s Disease. Int J Res Dev Pharm L Sci 11: 274.
Copyright: © 2025 Jain AS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract
Alzheimer's Disease (AD) is the most prevalent cause of progressive memory loss and dementia in older adults. Amyloid-Beta (Aβ) buildup and hyperphosphorylated tau are assumed to be a factor in the apoptotic neuronal death seen in Alzheimer's disease. Lack of effective treatments for Alzheimer's disease has led to a hunt for new therapeutic approaches. Endogenous molecules known as Neurosteroids (NSs) are produced in the nervous system from cholesterol. They have the ability to modify glutamate and GABA receptors, which serve as the main mediators of rapid excitatory and inhibitory neurotransmission in the brain, respectively because alterations in the glutamate and GABA neurotransmitter systems contributes to the pathogenesis of AD. This review focuses on the potential involvement of NSs in these diseases and how NSs might be created for therapeutic purposes.